Mymetics Corp (MYMX)

[Phosphene]

HIV virosomal vaccines have shown acceptable outcomes in clinical phase 1, and they may be available soon.

May 10, 2022. NIH Library of Medicine. 2.3.2 Virosomes. Italy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147349/

An HIV virosome-based vaccine has been prepared from influenza viruses by adsorbing some HIV-1 virulence antigens, such as gp41 and p1 peptides, and by including the adjuvant 3M-052, a thermostable adjuvant that increases virosome membrane rigidity [121,122].

In another study, a thermostable HIV-1 virosomal vaccine was composed of an influenza-enveloped virosome with HA, NA, lecithin, cephalin, and other phospholipids, with the addition of 3M-052, Toll-like receptor (TLR7/8) and the sugar trehalose [116].

Studies have shown that a recombinant HPV16 E7 influenza virosome induced strong CTL responses and prevented the development of an HPV16+ transformed cancer.

116. Amacker M., Smardon C., Mason L., Sorrell J., Jeffery K., Adler M., Bhoelan F., Belova O., Spengler M., Punnamoottil B., et al. New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes. Npj Vaccines. 2020;5:41. doi: 10.1038/s41541-020-0190-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

121. Duchemin M., Tudor D., Cottignies-Calamarte A., Bomsel M. Antibody-dependent cellular phagocytosis of HIV-1-infected cells is efficiently triggered by IgA targeting HIV-1 envelope subunit gp41. Front. Immunol. 2020;11:1141. doi: 10.3389/fimmu.2020.01141. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

122. Wong Y.T., Smardon C., Shirkhani K., Amacker M., Fleury S., Stegmann A.J.H. Oral Dispersible Vaccine Comprising Virosomes. PCT/EP2019/082940. [(accessed on 18 March 2022)];International Application No. 2019 June 28; Available online: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020109485